In CRC, preclinical and early translational evidence supports blockade of IL-8/CXCL1/2–CXCR1/2 pathways to reduce neutrophil/PMN-MDSC accumulation and improve sensitivity to immune checkpoint blockade. This evidence concerns the gene CXCL8 and colorectal carcinoma.